Use of RGM and its modulators

US8680239B2 · kind B2 · utility

Assignee

• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Bernhard Mueller · Neustadt, DE
• Paolo Macchi · Tübingen, DE
• Friedrich Bonhoeffer · Tübingen, DE
• Bernd Stahl · Tübingen, DE
• Matthias Mann · Odense, DK
• Jens S. Andersen · Odense, DK
• Philippe Monnier · Meylan, FR

Key dates

• Filing date: Jun 11, 2012
• Grant date: Mar 25, 2014
• Expiry date: Jun 11, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of a modulator of a polypeptide having or comprising an amino acid sequence as disclosed herein or of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for the preparation of a pharmaceutical composition for preventing, alleviating or treating diseases or conditions associated with the degeneration or injury of vertebrate nervous tissue, associated with seizures or associated with angiogenic disorders or disorders of the cardio-vascular system.